The FDA has approved Lumakras with Vectibix for adults with KRAS G12C-mutated metastatic colorectal cancer who received ...
The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) ...
The Food and Drug Administration has approved Amgen sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with ...
A meta-analysis showed that the development of liver metastases in patients with colorectal cancer was accompanied by a series of chromosomal deletions and gains in at least 15% of the tumor ...
Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with ...
FDA approved Braftovi, Erbitux, and mFOLFOX6 for BRAF V600E mutation-positive metastatic colorectal cancer. BREAKWATER trial showed a 61% objective response rate for the treatment group versus 40% for ...
PF-07921585 is under clinical development by Pfizer and currently in Phase I for Metastatic Colorectal Cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback